Kweihua Pharmaceutical's subsidiary has received acceptance for its application to market Ambroxol Hydrochloride Oral Solution. The drug is intended for conditions involving viscous sputum and difficulty expectorating, such as acute and chronic bronchitis. This marks a step forward in the company's drug development pipeline. AI
RANK_REASON This is a product approval application acceptance, not a full release or significant market event.
- Ambroxol Hydrochloride Oral Solution
- Harbin Kweihua Pharmaceutical Co., Ltd.
- Kweihua Pharmaceutical
- National Medical Products Administration
AI-generated summary · Google Gemini · from 1 sources. How we write summaries →